Voluntary Medical Male Circumcision2WTNCT03119337
Text-based Follow-up in Zimbabwe's Voluntary Medical Male Circumcision Program
A study testing Text-based follow-up in people with Voluntary Medical Male Circumcision, run by University of Washington at 5 sites in Zimbabwe.
Trial summary
Voluntary medical male circumcision (VMMC) in sub-Saharan Africa is safe: the average rate of moderate and severe adverse events (AEs) at the country level is 0.8%, corresponding to 99% of men healing without incident. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Voluntary Medical Male Circumcision
- What is being tested?
- Text-based follow-up
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 780 participants
- Where
- 5 sitesZimbabwe
- Study dates
- 18 Jun 2018to 30 Aug 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- are employees posted at the site;
- are at least 18 years of age or over;
- provide health care services to patients as part of the VMMC programs; and
- are able to provide written informed consent.
- For VMMC clients (Aims 1): Eligibility criteria for VMMC clients are:
- 18 years or older;
Show all 12Show fewer
- possession of own phone at enrollment;
- provides contact details (phone, physical location);
- receives surgical VMMC;
- willing to follow MoHCC VMMC protocols;
- willing to come in Day 14;
- Able and willing to respond to a questionnaire administered by phone 42 days after circumcision.
Who cannot join
- not willing to participate
- not willing to be recorded
- men without cell phones;
- those who chose PrePex as PrePex requires a device-removal visit 7 days after placement and has distinctly different follow-up protocols;
- men who have an inter-operative AE during routine VMMC will be withdrawn from the study as these men will have known, additional follow-up risks and mandatory in-person visits.
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
Zimbabwe5 sites
1. Chitungwiza Central Hospital
Chitungwiza, Stand Number 12096 Batanai ROAD Zengeza 4
2. South Medical Citimed Chitungwiza Hospital
Chitungwiza, Stand Number 14656 Zengeza 4
Zengeza 3 Clinic
Chitungwiza, Stand Number: 7723 Cheuka WAY Zengeza 3
5. Seke North Clinic
Seke North, Stand Number: 16106 UNIT G
4. Seke South Clinic
Seke South, Stand Number: 19188 UNIT L
About this study
Official title: Reducing Provider Workload While Preserving Patient Safety: A 2-Way Texting Intervention in Zimbabwe's Voluntary Medical Male Circumcision Program
Voluntary medical male circumcision (VMMC) in sub-Saharan Africa is safe: the average rate of moderate and severe adverse events (AEs) at the country level is 0.8%, corresponding to 99% of men healing without incident. To reach the global target of 20 million by 2018, VMMC productivity needs to double in countries already plagued by severe healthcare worker shortages like Zimbabwe. The ZAZIC consortium partners with the Zimbabwe Ministry of Health and Child Care (MoHCC) and performed over 120,000 VMMCs. Current VMMC care in Zimbabwe requires in-person, follow-up visits at post-operative days 2,7, and 42. Over 95% adhere to multiple follow-up visits within 14 days of VMMC. ZAZIC's program has an overall AE rate of 0.4%; therefore, overstretched clinic staff conducted more than 200,000 unnecessary reviews for VMMC clients without complications. High mobile phone ownership, severe healthcare worker shortages, and rapid VMMC scale up make ZAZIC's VMMC program an ideal setting to test a mobile health (mHealth) intervention to reduce provider workload while safeguarding patient safety. Through an un-blinded, prospective, randomized, control trial (RCT) in high-volume facilities providing VMMC, ZAZIC will implement an interactive, two-way texting (2wT) intervention to identify men healing without complication, allowing them to decline routine in-person follow up visits. 2wT will simultaneously identify men with any sign of an adverse event, encouraging rapid in-person follow-up when an AE is suspected on any day, reducing unnecessary visits while maintaining quality care. We aim to 1) determine if 2wT can safely reduce VMMC follow-up visits; 2) estimate the cost savings associated with 2wT over routine VMMC follow-up; and 3) assess the acceptability and feasibility of 2wT for further scale-up. It is expected that this intervention with be as safe as routine care while providing distinct advantages in terms of efficiency, costs, and reduced healthcare worker burden. This approach is innovative as it focuses on using a low-cost mHealth intervention to reduce provider workload without deterioration in quality care. The success of this intervention could lead to adoption of this intervention at the national level, increasing efficiency of VMMC scale up and reducing burdens on providers and patients
Read the detailed description
The investigators propose to maintain patient safety while reducing the substantial VMMC follow-up workload burden by using two-way mobile phone texts to provide in-person review only for men who indicate a desire or need for follow-up. This tailored approach to post-procedure VMMC care could reduce unnecessary visits and remove barriers for VMMC clients without deterioration of quality care. ZAZIC's diverse, expert team of researchers from the University of Washington, Seattle, USA; the University of Zimbabwe; Medic Mobile, Nairobi, Kenya; and Zimbabwean partner organizations will test this mHealth intervention. The investigators believe that bi-directional, interactive, text-based short message service (SMS) during the most critical 14 days after circumcision will help men identify and act on any sign of an adverse event, thereby seeking in-person follow-up only when an AE is suspected and reducing unnecessary visits. Reduced in-person follow-up could also free healthcare workers to perform additional VMMC surgeries. Using a prospective, randomized control trial (RCT), our intervention compares two groups of clients with cell phones: 1) standard care (control group) and 2) clients who receive and respond to a daily text with in-person follow-up only if desired or if an AE is suspected (intervention). Both arms complete a study-specific, Day 14, in-person, follow-up review for verification of self-reports (intervention) and comparison (control). Our specific aims are to:
Aim 1: Determine if 2-way texting can safely reduce VMMC follow-up visits Approach: Un-blinded, prospective, non-inferiority, RCT in high-volume facilities providing VMMC. Two-way texting (2wT) will provide interactive, text-based follow-up. 2wT men healing without complication could decline in-person follow-up; those with suspected AEs will be referred to in-person care. The investigators will compare the safety outcome of combined moderate or severe AE rate ≤ Day 14 post-VMMC and the workload outcome of average number of in-person follow-up visits between control and intervention arms.
Aim 2: Estimate the cost savings associated with 2wT over routine VMMC follow-up Approach: The investigators will determine the programmatic costs of 2wT from a systems perspective, including the technology [24], healthcare worker costs, and client perspective. The investigators will estimate the incremental intervention costs relative to standard practice to quantify gains in healthcare efficiency for scale-up and adoption.
Aim 3: Assess the acceptability and feasibility of 2wT for further scale-up Approach: Qualitative interviews with VMMC healthcare workers and brief quantitative interviews with 2wT clients inform intervention acceptance. Meetings with local researchers and collaborators will further assess feasibility, adaptation, open-source collaborative development, and system integration for replication and sustainability in Zimbabwe and the region.
APPROACH Study overview: Following usability testing with both healthcare workers and 2wT VMMC clients, The investigators will test if two-way texting (2wT) reduces unnecessary follow-up visits without compromising patient safety (Aim 1) using a randomized control trial in large, urban VMMC clinics. The investigators will assess the costs of 2wT from technology, healthcare worker, and client perspectives to determine the costs incurred by MoHCC if adopted for scale-up (Aim 2). The investigators will assess acceptability and feasibility working towards system integration and sustainability in Zimbabwe and beyond (Aim 3).
Aim 1: Technology overview: Studies that demonstrate the impacts of mHealth interventions too often have evaluated technologies that are made 'from scratch' and as a result are not robust enough to merit widespread replication [48, 74]. By partnering with a well-established non-profit mHealth organization, Medic Mobile (http://medicmobile.org/), and integrating with their existing software platform, open-source community and current efforts to integrate with existing health information systems (HIS) throughout sub-Saharan Africa, our team and proposed intervention are well positioned to scale up and sustain any promising results. Since 2008, Medic Mobile has been a leader in the global mHealth community [75-77], equipping more than 13,500 health workers serving over 8 million people across 23 countries. The Mobile Medic Toolkit is an Android-based application that supports texting in any language and works with or without internet connectivity on basic phones, smartphones, tablets, and computers [78]. The existing, well-proven, app-based Toolkit that will be the basis for 2wT provides an automated and prioritized list of upcoming tasks, guiding health worker through actions (e.g., response waiting, referral). The Toolkit provides real-time progress indicators such as texting delivery rates and response rates. Data from mobile users are replicated to Medic Mobile web app and analytics tools for real-time response. The platform is highly configurable, currently supporting evidence-backed workflows and program implementation related to ensuring safe deliveries [79], tracking tuberculosis patients [80], boosting immunization rates [81] and monitoring stocks of essential medicines [82]. These adaptable tools are free, open-source, and developed using human-centered design with input from people delivering care in the hardest-to-reach communities. While this technology has never been used in a VMMC program and requires adaptation of the clinical content, the existing 2wT software toolkit already contains the robust messaging features discussed in this proposal (Figure 2). The software adaptation process to alter and test alternative clinical content and the local specifications requires little additional software development. The adaptation process will be completed by co-investigator, Holeman, with additional technical and training support provided by Nairobi-based technical experts.
Study sites and population: In Zimbabwe, 81% of people already had mobile phone subscriptions in 2014 [83], indicating that the technology infrastructure exists and uptake is high. 2wT will be implemented in existing VMMC sites in the Chitungwiza District, a district purposefully selected for its high VMMC volume clinic locations. Chitungwiza District, a suburb of Harare, has an estimated 300,000 eligible, HIV-negative men ages 15-29; only 14% of eligible men have been circumcised to date. The investigators will implement 2wT in up to 5 ZAZIC VMMC sites in Chitungwiza, sites averaging 50-200 VMMC/month. About 80% of VMMC clients are surgical, rather than PrePex device-based, clients.
Study preparation: The investigators will conduct a rapid situation analysis with healthcare workers, VMMC clients, and stakeholders to assess suitable responses to VMMC client texts, setting standards for text responses and in-person follow-up. The investigators will modify existing usability surveys for this public health context. A small pilot with 50 VMMC clients will include usability testing with both 2wT clients and nurses implementing the 2wT system, illuminating system experiences from both perspectives. Usability results will inform in-box modification, message format preferences (SMS or WhatsApp) and optimal message delivery (timing, frequency, language preferences). Experience from study coordinator and other team members will add detail to inform 2wT adaptation and modification of Standard Operating Procedures before implementation. The investigators will examine local infrastructure (e.g. electricity and cell network), and explore 2wT cost reduction options (e.g., text bundling, free-call back numbers) and adapt accordingly
Standard VMMC care (Control arm): ZAZIC follows all MoHCC protocols based on WHO guidelines [20] including routine surgical VMMC follow-up on post-surgery days 2, 7 and 42 (Table 1). Patients may seek care outside scheduled visits for suspicion of AEs at any healthcare facility at any time but most often return to their VMMC site. Referral cards for VMMC clients provide local numbers for patients to text, call, or request a call back for emergencies. A standardized approach is used to assess, identify, and record the severity of AEs [51]. All VMMC care, from assessment of all AEs through complete healing, is provided free to clients from MoHCC. Clients who do not return to the clinic for follow-up on Day 2 or Day 7 are traced: 3 attempts by phone and then up to 3 attempts at in-person tracking after which they are considered lost to follow-up (LTFU) [52]. There is no tracing for Day 42 visits. For the purposes of this study, control arm VMMC clients will be asked to come in on Day 14 for an additional follow-up visit. No active follow-up is provided at Day 14.
VMMC care procedures (2wT arm): The investigators will conduct a prospective, un-blinded, randomized control trial (RCT) among VMMC clients in a 1:1 ratio of control to intervention. Study participants and clinic staff are not masked to treatment. Men in the 2wT will receive routine VMMC surgical care and counseling, including referral cards for emergencies. 2wT clients will receive automated daily texts from days 1-14 (Table 1 and Figure 3). It is free to receive call and texts; it costs $0.05 to send a SMS in Zimbabwe [84]. If they respond that they suspect no adverse event, no immediate follow-up action will be taken. If a 2wT VMMC client responds affirmatively to any daily text that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with the client to determine the symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier if an emergency is suspected. AE management will adhere to MoHCC standard care. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. Day 14 was chosen for verification because 95% of all AEs within the ZAZIC VMMC program are reported Day 14 or earlier [50], suggesting that most AEs have occurred by this time point. In a previous field study of AEs, the most common AEs of bleeding and infection were found a mean of 6.7 and 9.0 days, respectively, after VMMC [29], further supporting the 14 day period used in this and a previous study[5]. The Day 14 review will be conducted by routine VMMC providers according to MoHCC review guidelines. At Day 42, The investigators will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
- Conditions
- Voluntary Medical Male Circumcision
- Being tested
- Text-based follow-up
- Keywords
- male circumcision, text-based follow-up, Zimbabwe,
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Text-based follow-upOther
2wT clients will receive automated daily texts from days 1-14. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 42, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
| Study group | Role | What they receive |
|---|---|---|
| Text-based VMMC follow-up | Experimental | Follow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits. Receives: Other: Text-based follow-up |
| Routine VMMC follow-up care | No intervention | Routine VMMC follow up care with in person visits according to national guidelines. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cumulative adverse event (AE) rate (moderate or severe)
Incidence of AEs before Day 14 will be extracted from routine VMMC data for both 2wT and control. Incident AEs on Day 14 will be identified, classified, and graded for severity using routine MoHCC protocols [26] and recorded on routine VMMC AE forms. The investigators will compare cumulative rates of any moderate or severe AE ≤ Day 14 between groups using Fisher's exact test as the expected number of AEs is low. The rates will be calculated per arm as: (# moderate + severe AEs)/(total # VMMC clients who attend 2, 7 or 14 Day follow-up visit). Multivariate logistic regression models (any AE v none) will quantify the magnitude of difference, adjusting for any potential confounders.
Measured: ≤ Day 14 for each participant with analysis completed in year 1.
Mean number of in-person visits
To determine follow-up visit reduction, the investigators will compare the mean number of in-person visits for intervention and control using a t-test. A multivariate linear regression model will further quantify the effect of intervention on visit reduction, adjusting for potential confounders.
Measured: Before 42 day visit for each participant with analysis completed in year 1.
2wT costs
The investigators will calculate the relative costs and outcomes (effects) of intervention versus control, including costs for technology, healthcare worker time, and client considerations (travel, text costs, missed work). The investigators will conduct both activity-based costing from the implementation perspective and from the technology perspective to extrapolate results as costs that would be incurred by the MoHCC should they elect widespread scale up of 2wT.
Measured: The costing data collection will be completed by April 2018 at the completion of all study participant follow-up. Analysis will conclude in year 1
2WT acceptability
2wT acceptability, using study recruitment and enrollment logs in addition to the texting database, the investigators will describe levels of acceptance, participation, refusal and drop-out. The investigators will carry out key informant interviews (KIIs) with up to 8 health care workers to gauge acceptability, satisfaction, identify facilitators and barriers to program success, and ascertain suggestions for intervention improvement. KIIs will be audio recorded and transcribed. The investigators will also implement questionnaires at the Day 14 visit with a subset of 100 2wT VMMC clients to gauge satisfaction, estimate direct and indirect costs (time away from work, transportation costs), and ascertain suggestions for intervention improvement.
Measured: The acceptability activities will be completed by April 2018 at the completion of all study participant follow-up with analysis to commence after that point. Analysis will conclude in year 1.
2WT feasibility
For feasibility, costing data will be combined with usability and acceptability information.
Measured: The feasibility activities be completed by April 2018 at the completion of all study participant follow-up with analysis to commence after that point. Analysis will conclude in year 1.
Secondary outcomes (3)
AE rates on Day 14
AE rates on Day 14
Measured: Day 14 data collection for each participant with analysis to be completed in year 1.
severity of AEs.
severity of AEs.
Measured: Day 14 data collection for each participant with analysis to be completed in year 1.
time between 2wT AE text reporting and follow-up
time between 2wT AE text reporting and follow-up
Measured: Day 14 data collection for each participant with analysis to be completed in year 1.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2017
- Study start18 Jun 2018
- Primary completion28 Feb 2019
- Study completion30 Aug 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Voluntary Medical Male CircumcisionStudies of the same condition, open and under way.
- More trials run by University of WashingtonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The investigators will conduct a prospective, un-blinded, randomized control trial (RCT) among VMMC clients in a 1:1 ratio of control to intervention. Study participants and clinic staff are not masked to treatment.
- Masking
- None (open label)
- Enrolment
- 780 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Washington
- Sponsor type
- University, hospital or other
- Collaborators
- Medic Mobile, International Training and Education Center for Health, ZICHIRe, University of Zimbabwe
- Responsible party
- Principal investigator, Caryl Feldacker, University of Washington
- Investigators
- Caryl Feldacker, PhD, MPH, Principal investigator, University of Washington
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03119337
- Sponsor's protocol ID
- STUDY00001839
- Acronym
- 2WT
- Status last verified
- Mar 2020
- First submitted
- 31 Mar 2017
- Last updated
- 18 Mar 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: We do not plan to share IPD with other researchers.
Publications
Palmer MJ, Henschke N, Villanueva G, Maayan N, Bergman H, Glenton C, Lewin S, Fonhus MS, Tamrat T, Mehl GL, Free C. Targeted client communication via mobile devices for improving sexual and reproductive health. Cochrane Database Syst Rev. 2020 Jul 14;8(8):CD013680. doi: 10.1002/14651858.CD013680.
PubMed 32779730Feldacker C, Holeman I, Murenje V, Xaba S, Korir M, Wambua B, Makunike-Chikwinya B, Holec M, Barnhart S, Tshimanga M. Usability and acceptability of a two-way texting intervention for post-operative follow-up for voluntary medical male circumcision in Zimbabwe. PLoS One. 2020 Jun 16;15(6):e0233234. doi: 10.1371/journal.pone.0233234. eCollection 2020.
PubMed 32544161Feldacker C, Murenje V, Holeman I, Xaba S, Makunike-Chikwinya B, Korir M, Gundidza PT, Holec M, Barnhart S, Tshimanga M. Reducing Provider Workload While Preserving Patient Safety: A Randomized Control Trial Using 2-Way Texting for Postoperative Follow-up in Zimbabwe's Voluntary Medical Male Circumcision Program. J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):16-23. doi: 10.1097/QAI.0000000000002198.
PubMed 31809358Feldacker C, Murenje V, Barnhart S, Xaba S, Makunike-Chikwinya B, Holeman I, Tshimanga M. Reducing provider workload while preserving patient safety via a two-way texting intervention in Zimbabwe's voluntary medical male circumcision program: study protocol for an un-blinded, prospective, non-inferiority, randomized controlled trial. Trials. 2019 Jul 23;20(1):451. doi: 10.1186/s13063-019-3470-9.
PubMed 31337414
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reducing Provider Workload While Preserving Patient Safety: A 2-Way Texting Intervention in Zimbabwe's Voluntary Medical Male Circumcision Program
- ClinicalTrials.gov ID
- NCT03119337
- Acronym / sponsor ID
- 2WT / STUDY00001839
- Conditions
- Voluntary Medical Male Circumcision
- Keywords
- male circumcision, text-based follow-up, Zimbabwe,
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 780 participants (actual)
- Lead sponsor
- University of WashingtonUniversity, hospital or other
- Collaborators
- Medic Mobile, International Training and Education Center for Health, ZICHIRe, University of Zimbabwe
- Study start
- 18 Jun 2018 (actual)
- Primary completion
- 28 Feb 2019 (actual)
- Study completion
- 30 Aug 2019 (actual)
- First posted
- 18 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Voluntary medical male circumcision (VMMC) in sub-Saharan Africa is safe: the average rate of moderate and severe adverse events (AEs) at the country level is 0.8%, corresponding to 99% of men healing without incident. To reach the global target of 20 million by 2018, VMMC productivity needs to double in countries already plagued by severe healthcare worker shortages like Zimbabwe. The ZAZIC consortium partners with the Zimbabwe Ministry of Health and Child Care (MoHCC) and performed over 120,000 VMMCs. Current VMMC care in Zimbabwe requires in-person, follow-up visits at post-operative days 2,7, and 42. Over 95% adhere to multiple follow-up visits within 14 days of VMMC. ZAZIC's program has an overall AE rate of 0.4%; therefore, overstretched clinic staff conducted more than 200,000 unnecessary reviews for VMMC clients without complications. High mobile phone ownership, severe healthcare worker shortages, and rapid VMMC scale up make ZAZIC's VMMC program an ideal setting to test a mobile health (mHealth) intervention to reduce provider workload while safeguarding patient safety. Through an un-blinded, prospective, randomized, control trial (RCT) in high-volume facilities providing VMMC, ZAZIC will implement an interactive, two-way texting (2wT) intervention to identify men healing without complication, allowing them to decline routine in-person follow up visits. 2wT will simultaneously identify men with any sign of an adverse event, encouraging rapid in-person follow-up when an AE is suspected on any day, reducing unnecessary visits while maintaining quality care. We aim to 1) determine if 2wT can safely reduce VMMC follow-up visits; 2) estimate the cost savings associated with 2wT over routine VMMC follow-up; and 3) assess the acceptability and feasibility of 2wT for further scale-up. It is expected that this intervention with be as safe as routine care while providing distinct advantages in terms of efficiency, costs, and reduced healthcare worker burden. This approach is innovative as it focuses on using a low-cost mHealth intervention to reduce provider workload without deterioration in quality care. The success of this intervention could lead to adoption of this intervention at the national level, increasing efficiency of VMMC scale up and reducing burdens on providers and patients
Detailed description
The investigators propose to maintain patient safety while reducing the substantial VMMC follow-up workload burden by using two-way mobile phone texts to provide in-person review only for men who indicate a desire or need for follow-up. This tailored approach to post-procedure VMMC care could reduce unnecessary visits and remove barriers for VMMC clients without deterioration of quality care. ZAZIC's diverse, expert team of researchers from the University of Washington, Seattle, USA; the University of Zimbabwe; Medic Mobile, Nairobi, Kenya; and Zimbabwean partner organizations will test this mHealth intervention. The investigators believe that bi-directional, interactive, text-based short message service (SMS) during the most critical 14 days after circumcision will help men identify and act on any sign of an adverse event, thereby seeking in-person follow-up only when an AE is suspected and reducing unnecessary visits. Reduced in-person follow-up could also free healthcare workers to perform additional VMMC surgeries. Using a prospective, randomized control trial (RCT), our intervention compares two groups of clients with cell phones: 1) standard care (control group) and 2) clients who receive and respond to a daily text with in-person follow-up only if desired or if an AE is suspected (intervention). Both arms complete a study-specific, Day 14, in-person, follow-up review for verification of self-reports (intervention) and comparison (control). Our specific aims are to:
Aim 1: Determine if 2-way texting can safely reduce VMMC follow-up visits Approach: Un-blinded, prospective, non-inferiority, RCT in high-volume facilities providing VMMC. Two-way texting (2wT) will provide interactive, text-based follow-up. 2wT men healing without complication could decline in-person follow-up; those with suspected AEs will be referred to in-person care. The investigators will compare the safety outcome of combined moderate or severe AE rate ≤ Day 14 post-VMMC and the workload outcome of average number of in-person follow-up visits between control and intervention arms.
Aim 2: Estimate the cost savings associated with 2wT over routine VMMC follow-up Approach: The investigators will determine the programmatic costs of 2wT from a systems perspective, including the technology [24], healthcare worker costs, and client perspective. The investigators will estimate the incremental intervention costs relative to standard practice to quantify gains in healthcare efficiency for scale-up and adoption.
Aim 3: Assess the acceptability and feasibility of 2wT for further scale-up Approach: Qualitative interviews with VMMC healthcare workers and brief quantitative interviews with 2wT clients inform intervention acceptance. Meetings with local researchers and collaborators will further assess feasibility, adaptation, open-source collaborative development, and system integration for replication and sustainability in Zimbabwe and the region.
APPROACH Study overview: Following usability testing with both healthcare workers and 2wT VMMC clients, The investigators will test if two-way texting (2wT) reduces unnecessary follow-up visits without compromising patient safety (Aim 1) using a randomized control trial in large, urban VMMC clinics. The investigators will assess the costs of 2wT from technology, healthcare worker, and client perspectives to determine the costs incurred by MoHCC if adopted for scale-up (Aim 2). The investigators will assess acceptability and feasibility working towards system integration and sustainability in Zimbabwe and beyond (Aim 3).
Aim 1: Technology overview: Studies that demonstrate the impacts of mHealth interventions too often have evaluated technologies that are made 'from scratch' and as a result are not robust enough to merit widespread replication [48, 74]. By partnering with a well-established non-profit mHealth organization, Medic Mobile (http://medicmobile.org/), and integrating with their existing software platform, open-source community and current efforts to integrate with existing health information systems (HIS) throughout sub-Saharan Africa, our team and proposed intervention are well positioned to scale up and sustain any promising results. Since 2008, Medic Mobile has been a leader in the global mHealth community [75-77], equipping more than 13,500 health workers serving over 8 million people across 23 countries. The Mobile Medic Toolkit is an Android-based application that supports texting in any language and works with or without internet connectivity on basic phones, smartphones, tablets, and computers [78]. The existing, well-proven, app-based Toolkit that will be the basis for 2wT provides an automated and prioritized list of upcoming tasks, guiding health worker through actions (e.g., response waiting, referral). The Toolkit provides real-time progress indicators such as texting delivery rates and response rates. Data from mobile users are replicated to Medic Mobile web app and analytics tools for real-time response. The platform is highly configurable, currently supporting evidence-backed workflows and program implementation related to ensuring safe deliveries [79], tracking tuberculosis patients [80], boosting immunization rates [81] and monitoring stocks of essential medicines [82]. These adaptable tools are free, open-source, and developed using human-centered design with input from people delivering care in the hardest-to-reach communities. While this technology has never been used in a VMMC program and requires adaptation of the clinical content, the existing 2wT software toolkit already contains the robust messaging features discussed in this proposal (Figure 2). The software adaptation process to alter and test alternative clinical content and the local specifications requires little additional software development. The adaptation process will be completed by co-investigator, Holeman, with additional technical and training support provided by Nairobi-based technical experts.
Study sites and population: In Zimbabwe, 81% of people already had mobile phone subscriptions in 2014 [83], indicating that the technology infrastructure exists and uptake is high. 2wT will be implemented in existing VMMC sites in the Chitungwiza District, a district purposefully selected for its high VMMC volume clinic locations. Chitungwiza District, a suburb of Harare, has an estimated 300,000 eligible, HIV-negative men ages 15-29; only 14% of eligible men have been circumcised to date. The investigators will implement 2wT in up to 5 ZAZIC VMMC sites in Chitungwiza, sites averaging 50-200 VMMC/month. About 80% of VMMC clients are surgical, rather than PrePex device-based, clients.
Study preparation: The investigators will conduct a rapid situation analysis with healthcare workers, VMMC clients, and stakeholders to assess suitable responses to VMMC client texts, setting standards for text responses and in-person follow-up. The investigators will modify existing usability surveys for this public health context. A small pilot with 50 VMMC clients will include usability testing with both 2wT clients and nurses implementing the 2wT system, illuminating system experiences from both perspectives. Usability results will inform in-box modification, message format preferences (SMS or WhatsApp) and optimal message delivery (timing, frequency, language preferences). Experience from study coordinator and other team members will add detail to inform 2wT adaptation and modification of Standard Operating Procedures before implementation. The investigators will examine local infrastructure (e.g. electricity and cell network), and explore 2wT cost reduction options (e.g., text bundling, free-call back numbers) and adapt accordingly
Standard VMMC care (Control arm): ZAZIC follows all MoHCC protocols based on WHO guidelines [20] including routine surgical VMMC follow-up on post-surgery days 2, 7 and 42 (Table 1). Patients may seek care outside scheduled visits for suspicion of AEs at any healthcare facility at any time but most often return to their VMMC site. Referral cards for VMMC clients provide local numbers for patients to text, call, or request a call back for emergencies. A standardized approach is used to assess, identify, and record the severity of AEs [51]. All VMMC care, from assessment of all AEs through complete healing, is provided free to clients from MoHCC. Clients who do not return to the clinic for follow-up on Day 2 or Day 7 are traced: 3 attempts by phone and then up to 3 attempts at in-person tracking after which they are considered lost to follow-up (LTFU) [52]. There is no tracing for Day 42 visits. For the purposes of this study, control arm VMMC clients will be asked to come in on Day 14 for an additional follow-up visit. No active follow-up is provided at Day 14.
VMMC care procedures (2wT arm): The investigators will conduct a prospective, un-blinded, randomized control trial (RCT) among VMMC clients in a 1:1 ratio of control to intervention. Study participants and clinic staff are not masked to treatment. Men in the 2wT will receive routine VMMC surgical care and counseling, including referral cards for emergencies. 2wT clients will receive automated daily texts from days 1-14 (Table 1 and Figure 3). It is free to receive call and texts; it costs $0.05 to send a SMS in Zimbabwe [84]. If they respond that they suspect no adverse event, no immediate follow-up action will be taken. If a 2wT VMMC client responds affirmatively to any daily text that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with the client to determine the symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier if an emergency is suspected. AE management will adhere to MoHCC standard care. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. Day 14 was chosen for verification because 95% of all AEs within the ZAZIC VMMC program are reported Day 14 or earlier [50], suggesting that most AEs have occurred by this time point. In a previous field study of AEs, the most common AEs of bleeding and infection were found a mean of 6.7 and 9.0 days, respectively, after VMMC [29], further supporting the 14 day period used in this and a previous study[5]. The Day 14 review will be conducted by routine VMMC providers according to MoHCC review guidelines. At Day 42, The investigators will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- The investigators will conduct a prospective, un-blinded, randomized control trial (RCT) among VMMC clients in a 1:1 ratio of control to intervention. Study participants and clinic staff are not masked to treatment.
| Arm | Type | Receives |
|---|---|---|
| Text-based VMMC follow-up | Experimental | Other: Text-based follow-upFollow-up conducted via daily text not through mandatory in person visits. Men may elect to come to the clinic if concerned about any complications but have no routine, scheduled follow-up visits. |
| Routine VMMC follow-up care | No intervention | –Routine VMMC follow up care with in person visits according to national guidelines. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- are employees posted at the site;
- are at least 18 years of age or over;
- provide health care services to patients as part of the VMMC programs; and
- are able to provide written informed consent.
- 18 years or older;
Key exclusion criteria (5 listed)
- not willing to participate
- not willing to be recorded
- men without cell phones;
- those who chose PrePex as PrePex requires a device-removal visit 7 days after placement and has distinctly different follow-up protocols;
- men who have an inter-operative AE during routine VMMC will be withdrawn from the study as these men will have known, additional follow-up risks and mandatory in-person visits.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Text-based follow-up2wT clients will receive automated daily texts from days 1-14. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 42, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion. | Other | Text-based VMMC follow-up |
Primary outcome
Cumulative adverse event (AE) rate (moderate or severe)
Time frame: ≤ Day 14 for each participant with analysis completed in year 1.
Incidence of AEs before Day 14 will be extracted from routine VMMC data for both 2wT and control. Incident AEs on Day 14 will be identified, classified, and graded for severity using routine MoHCC protocols [26] and recorded on routine VMMC AE forms. The investigators will compare cumulative rates of any moderate or severe AE ≤ Day 14 between groups using Fisher's exact test as the expected number of AEs is low. The rates will be calculated per arm as: (# moderate + severe AEs)/(total # VMMC clients who attend 2, 7 or 14 Day follow-up visit). Multivariate logistic regression models (any AE v none) will quantify the magnitude of difference, adjusting for any potential confounders.
Mean number of in-person visits
Time frame: Before 42 day visit for each participant with analysis completed in year 1.
To determine follow-up visit reduction, the investigators will compare the mean number of in-person visits for intervention and control using a t-test. A multivariate linear regression model will further quantify the effect of intervention on visit reduction, adjusting for potential confounders.
2wT costs
Time frame: The costing data collection will be completed by April 2018 at the completion of all study participant follow-up. Analysis will conclude in year 1
The investigators will calculate the relative costs and outcomes (effects) of intervention versus control, including costs for technology, healthcare worker time, and client considerations (travel, text costs, missed work). The investigators will conduct both activity-based costing from the implementation perspective and from the technology perspective to extrapolate results as costs that would be incurred by the MoHCC should they elect widespread scale up of 2wT.
2WT acceptability
Time frame: The acceptability activities will be completed by April 2018 at the completion of all study participant follow-up with analysis to commence after that point. Analysis will conclude in year 1.
2wT acceptability, using study recruitment and enrollment logs in addition to the texting database, the investigators will describe levels of acceptance, participation, refusal and drop-out. The investigators will carry out key informant interviews (KIIs) with up to 8 health care workers to gauge acceptability, satisfaction, identify facilitators and barriers to program success, and ascertain suggestions for intervention improvement. KIIs will be audio recorded and transcribed. The investigators will also implement questionnaires at the Day 14 visit with a subset of 100 2wT VMMC clients to gauge satisfaction, estimate direct and indirect costs (time away from work, transportation costs), and ascertain suggestions for intervention improvement.
2WT feasibility
Time frame: The feasibility activities be completed by April 2018 at the completion of all study participant follow-up with analysis to commence after that point. Analysis will conclude in year 1.
For feasibility, costing data will be combined with usability and acceptability information.
3 secondary outcomes
AE rates on Day 14
Time frame: Day 14 data collection for each participant with analysis to be completed in year 1.
severity of AEs.
Time frame: Day 14 data collection for each participant with analysis to be completed in year 1.
time between 2wT AE text reporting and follow-up
Time frame: Day 14 data collection for each participant with analysis to be completed in year 1.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2020.
- Derived from this study: PubMed 32779730Palmer MJ, Henschke N, Villanueva G, Maayan N, Bergman H, Glenton C, Lewin S, Fonhus MS, Tamrat T, Mehl GL, Free C. Targeted client communication via mobile devices for improving sexual and reproductive health. Cochrane Database Syst Rev. 2020 Jul 14;8(8):CD013680. doi: 10.1002/14651858.CD013680.
- Derived from this study: PubMed 32544161Feldacker C, Holeman I, Murenje V, Xaba S, Korir M, Wambua B, Makunike-Chikwinya B, Holec M, Barnhart S, Tshimanga M. Usability and acceptability of a two-way texting intervention for post-operative follow-up for voluntary medical male circumcision in Zimbabwe. PLoS One. 2020 Jun 16;15(6):e0233234. doi: 10.1371/journal.pone.0233234. eCollection 2020.
- Derived from this study: PubMed 31809358Feldacker C, Murenje V, Holeman I, Xaba S, Makunike-Chikwinya B, Korir M, Gundidza PT, Holec M, Barnhart S, Tshimanga M. Reducing Provider Workload While Preserving Patient Safety: A Randomized Control Trial Using 2-Way Texting for Postoperative Follow-up in Zimbabwe's Voluntary Medical Male Circumcision Program. J Acquir Immune Defic Syndr. 2020 Jan 1;83(1):16-23. doi: 10.1097/QAI.0000000000002198.
- Derived from this study: PubMed 31337414Feldacker C, Murenje V, Barnhart S, Xaba S, Makunike-Chikwinya B, Holeman I, Tshimanga M. Reducing provider workload while preserving patient safety via a two-way texting intervention in Zimbabwe's voluntary medical male circumcision program: study protocol for an un-blinded, prospective, non-inferiority, randomized controlled trial. Trials. 2019 Jul 23;20(1):451. doi: 10.1186/s13063-019-3470-9.
- Individual participant dataSharing planned: No. We do not plan to share IPD with other researchers.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Caryl Feldacker, PhD, MPH principal investigator
University of Washington
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Text-based follow-up in people with Voluntary Medical Male Circumcision, run by University of Washington at 5 sites in Zimbabwe.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Zimbabwe. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cumulative adverse event (AE) rate (moderate or severe) (time frame: ≤ Day 14 for each participant with analysis completed in year 1.). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03119337, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2020.